Anest. intenziv. Med. 2013;24(6):403-409

The heart in septic shock and beta-blockade. Reconsidering the paradox?Intesive Care Medicine - Special Article

Matějovič Martin
I. interní klinika, Lékařská fakulta v Plzni, Univerzita Karlova v Praze, Fakultní nemocnice Plzeň
Biomedicínské centrum, Lékařská fakulta v Plzni, Univerzita Karlova v Praze, Plzeň, Česká republika

Myocardial depression is a well-recognized consequence of septic shock. A growing body of evidence suggests that excessive catecholamine levels exert toxic effects on the heart, thereby contributing to the development of septic myocardial dysfunction. Although seemingly counter-intuitive, beta-blockade aimed at the attenuation of the sympatho-adrenergic stress may represent a plausible concept in protecting the heart during septic shock. Limited experimental and clinical evidence indicates that careful control of heart rate using short-acting beta-1 selective blockers might economize cardiac work without exerting adverse systemic haemodynamiceffects in septic subjects. Rigorous testing of this concept in randomized clinical trials is needed before it can be implemented in clinical practice. This article briefly introduces the concept of de-catecholaminisation and discusses the pros and cons of this emerging paradigm.

Keywords: septic shock; beta-blockade; esmolol; hemodynamics; heart failure

Published: December 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Matějovič M. The heart in septic shock and beta-blockade. Reconsidering the paradox? Anest. intenziv. Med. 2013;24(6):403-409.
Download citation

References

  1. Rudiger, A., Singer, M. The heart in sepsis: from basic mechanisms to clinical management. Curr. Vasc. Pharmacol., 2013, 11, 2, p. 187-195. Go to original source... Go to PubMed...
  2. Chvojka, J., Matějovič, M. Srdce u nemocných v sepsi - septická kardiomyopatie. Postgrad. Med., 2012, 10, p. 12-18.
  3. Park, J. H., Kang, S. J., Song, J. K., Kim, H. K., Lim, C. M., Kang, D. H., Koh, Y. Left ventricular apical ballooning due to severe physical stress in patients admitted to the medical ICU. Chest, 2005, 128, 1, p. 296-302. Go to original source... Go to PubMed...
  4. Balik, M., Rulisek, J., Leden, P., Zakharchenko, M., Otahal, M., Bartakova, H., Korinek, J. Concomitant use of beta-1 adrenoreceptor blocker and norepinephrine in patients with septic shock. Wien Klin Wochenschr., 2012, 124, 15-16, p. 552-556. Go to original source... Go to PubMed...
  5. Suzuki, T., Morisaki, H., Serita, R., Yamamoto, M., Kotake, Y., Ishizaka, A., Takeda, J. Infusion of the beta-adrenergic blocker esmolol attenuates myocardial dysfunction in septic rats. Crit. Care Med., 2005, 33, 10, p. 2294-2301. Go to original source... Go to PubMed...
  6. Hagiwara, S., Iwasaka, H., Maeda, H., Noguchi, T. Landiolol, an ultrashort-acting beta1-adrenoceptor antagonist, has protective effects in an LPS-induced systemic inflammation model. Shock, 2009, 31, 5, p. 515-520. Go to original source... Go to PubMed...
  7. Ackland, G. L., Yao, S. T., Rudiger, A., Dyson, A., Stidwill, R., Poputnikov, D., Singer, M., Gourine, A. V. Cardioprotection, attenuated systemic inflammation, and survival benefit of beta1-adrenoceptor blockade in severe sepsis in rats. Crit. Care Med., 2010 38, 2, p. 388-394. Go to original source... Go to PubMed...
  8. Aboab, J., Sebille, V., Jourdain, M., Mangalaboyi, J., Gharbi, M.,Mansart, A., Annane, D. Effects of esmolol on systemic and pulmonary hemodynamics and on oxygenation in pigs with hypodynamic endotoxin shock. Intensive Care Med., 2011 37, 8, p. 1344-1351. Go to original source... Go to PubMed...
  9. Schmitz, D., Wilsenack, K., Lendemanns, S., Schedlowski, M., Oberbeck, R. Beta-Adrenergic blockade during systemic inflammation: impact on cellular immune functions and survival in a murine model of sepsis. Resuscitation, 2007, 72, 2, p. 286-294. Go to original source... Go to PubMed...
  10. Gore, D. C., Wolfe, R. R. Hemodynamic and metabolic effects of selective beta1 adrenergic blockade during sepsis. Surgery, 2006, 139, 5, p. 686-694. Go to original source... Go to PubMed...
  11. Schmittinger, C. A., Dünser, M. W., Haller, M., Ulmer, H., Luckner, G., Torgersen, C., Jochberger, S., Hasibeder, W. R. Combined milrinone and enteral metoprolol therapy in patients with septic myocardial depression. Crit. Care, 2008, 12, 4, p. R99. Go to original source... Go to PubMed...
  12. Novotny, N. M., Lahm, T., Markel, T. A., Crisostomo, P. R., Wang, M., Wang, Y., Ray, R., Tan, J., Al-Azzawi, D., Meldrum, D. R. Beta-blockers in sepsis: reexamining the evidence. Shock, 2009, 31, p. 113-119. Go to original source... Go to PubMed...
  13. Rudiger, A. Beta-block the septic heart. Crit. Care Med., 2010, 38, p. S608-S612. Go to original source... Go to PubMed...
  14. de Montmollin, E., Aboab, J., Mansart, A., Annane, D. Bench-to-bedside review: Beta-adrenergic modulation in sepsis. Crit. Care, 2009, 13, p. 230. Go to original source... Go to PubMed...
  15. Morelli, A., Ertmer, C., Westphal, M., Rehberg, S., Kampmeier, T., Ligges, S., Orecchioni, A., D'Egidio, A., D'Ippoliti, F., Raffone, C., Venditti, M., Guarracino, F., Girardis, M., Tritapepe, L., Pietropaoli, P., Mebazaa, A., Singer, M. Effect of Heart Rate Control With Esmolol on Hemodynamic and Clinical Outcomes in Patients With Septic Shock: A Randomized Clinical Trial. JAMA, 2013, Oct 9. doi: 10.1001/jama.2013.278477. Go to original source... Go to PubMed...
  16. Morelli, A., Donati, A., Ertmer, C., Rehberg, S., Kampmeier, T., Orecchioni, A., D'Egidio, A., Cecchini, V., Landoni, G., Pietropaoli, P., Westphal, M., Venditti, M., Mebazaa, A., Singer, M.Microvascular effects of heart rate control with esmolol inpatients with septic shock: a pilot study. Crit. Care Med., 2013, 41, 9, p. 2162-218. Go to original source... Go to PubMed...
  17. Chertow, G. M., Palevsky, P. M., Greene, T. Studying the prevention of acute kidney injury: lessons from an 18th-century mathematician. Clin. J. Am. Soc. Nephrol., 2006, 1, 5, p. 1124-1127. Go to original source... Go to PubMed...
  18. Sander, O., Welters, I. D., Foëx, P., Sear, J. W. Impact of prolonged elevated heart rate on incidence of major cardiac events in critically ill patients with a high risk of cardiac complications. Crit. Care Med., 2005, 33, 1, p. 81-88. Go to original source... Go to PubMed...
  19. POISE Study Group, Devereaux, P. J., Yang, H., Yusuf, S., Guyatt, G., Leslie, K., Villar, J. C., Xavier, D., Chrolavicius, S., Greenspan, L., Pogue, J., Pais, P., Liu, L., Xu, S., Málaga, G., Avezum, A., Chan, M., Montori, V. M., Jacka, M., Choi, P. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet, 2008, 371, 9627, p. 1839-1847. Go to original source... Go to PubMed...
  20. Chen, Z. M., Pan, H. C., Chen, Y. P., Peto, R., Collins, R., Jiang, L. X., Xie, J. X., Liu, L. S.; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet, 2005, 5, 366, 9497, p. 1622-1632. Go to original source... Go to PubMed...
  21. Macchia, A., Romero, M., Comignani, P. D., Mariani, J., D'Ettorre, A., Prini, N., Santopinto, M., Tognoni, G. Previous prescription of β-blockers is associated with reduced mortality among patients hospitalized in intensive care units for sepsis. Crit. Care Med., 2012, 40, 10, p. 2768-2772. Go to original source... Go to PubMed...
  22. Christensen, S., Johansen, M. B., Tønnesen, E., Larsson, A., Pedersen, L., Lemeshow, S., Sørensen, H. T. Preadmission beta-blocker use and 30-day mortality among patients in intensive care: a cohort study. Crit. Care, 2011, 15, 2, p. R87. Go to original source... Go to PubMed...
  23. Cvachovec, K. Beta-blockers in flow of time - view of an anaesthesiologist and intensivist. Cas. Lek. Cesk., 2010, 149, 6, p. 288-290. Go to PubMed...
  24. Magder, S. A. The ups and downs of heart rate. Crit. Care Med., 2012, 40, 1, p. 239-245. Go to original source... Go to PubMed...




Anesteziologie a intenzivní medicína

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.